ArticleScientific reports2025
Advancing the accuracy of clathrin protein prediction through multi-source protein language models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.Protein science : a publication of the Protein Society · 2026Article
- An Explainable Deep Learning Model for Clathrin Protein Prediction Using a DCT-Enhanced Position-Specific Scoring Matrix.Current drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Clathrin is a key cytoplasmic protein that serves as the predominant structural element in the formation of coated vesicles. Specifically, clarithin enables the scission of newly formed vesicles from the plasma membrane's cytoplasmic face. Efficient and accurate identification of clathrins is essential for understanding human diseases and aiding drug target development. Recent advancements in computational methods for identifying clathrins using sequence data have greatly improved large-scale clathrin screening. Here, we propose a high-accuracy computational approach, termed PLM-CLA, to achieve more accurate identification of clathrins. In PLM-CLA, we leveraged multi-source pre-trained protein language models (PLMs), which were trained on large-scale protein sequences from multiple database sources, including ProtT5-BFD, ProtT5-UR50, ProstT5, and ESM-2. These models were used to encode complementary feature embeddings, capturing diverse and valuable information. To the best of our knowledge, PLM-CLA is the first attempt designed using various PLM-based embeddings to identify clathrins. To enhance prediction performance, we utilized a feature selection method to optimize these fused feature embeddings. Finally, we employed a long short-term memory (LSTM) neural network model coupled with the optimal feature subset to identify clathrins. Benchmarking experiments, including independent tests, showed that PLM-CLA significantly outperformed state-of-the-art methods, achieving an accuracy of 0.961, MCC of 0.917, and AUC of 0.997. Furthermore, PLM-CLA secured outstanding performance in terms of MCC, with values of 0.971 and 0.904 on two existing independent test datasets. We anticipate that the proposed PLM-CLA model will serve as a promising tool for large-scale identification of clathrins in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.